Other formats:
BibTeX
LaTeX
RIS
@article{1751716,
author = {Schjesvold, F. and Robak, P. and Pour, Luděk and Aschan, J. and Sonneveld, P.},
article_location = {London},
article_number = {11},
doi = {http://dx.doi.org/10.2217/fon-2020-0024},
keywords = {alkylating agent; melflufen; MM; multiple myeloma; Phase III study; relapsed refractory multiple myeloma; RRMM},
language = {eng},
issn = {1479-6694},
journal = {Future Oncology},
title = {OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma},
url = {https://www.futuremedicine.com/doi/10.2217/fon-2020-0024?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed},
volume = {16},
year = {2020}
}
TY - JOUR
ID - 1751716
AU - Schjesvold, F. - Robak, P. - Pour, Luděk - Aschan, J. - Sonneveld, P.
PY - 2020
TI - OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma
JF - Future Oncology
VL - 16
IS - 11
SP - 631-641
EP - 631-641
PB - Future Medicine Ltd.
SN - 14796694
KW - alkylating agent
KW - melflufen
KW - MM
KW - multiple myeloma
KW - Phase III study
KW - relapsed refractory multiple myeloma
KW - RRMM
UR - https://www.futuremedicine.com/doi/10.2217/fon-2020-0024?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
N2 - Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the disease. Here we describe the rationale and design of OCEAN (NCT03151811), a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melflufen + dexamethasone versus pomalidomide + dexamethasone. Eligible patients with relapsed refractory multiple myeloma have received 2-4 previous treatments and are refractory to both lenalidomide and their last treatment. Patients are excluded if they have previously received pomalidomide. The primary endpoint is progression-free survival, and key secondary endpoints include overall response rate, duration of response and overall survival.
ER -
SCHJESVOLD, F., P. ROBAK, Luděk POUR, J. ASCHAN and P. SONNEVELD. OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma. \textit{Future Oncology}. London: Future Medicine Ltd., 2020, vol.~16, No~11, p.~631-641. ISSN~1479-6694. Available from: https://dx.doi.org/10.2217/fon-2020-0024.
|
